Associated Papers
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance.
Nussinov R et al.
Annual Review of Pharmacology and Toxicology, 2024
Enhanced interpretation of 935 hotspot and non-hotspot RAS variants using evidence-based structural bioinformatics.
Tripathi S et al.
Computational and Structural Biotechnology Journal, 2022
34976316 (PubMed )
Supplement: mmc1.docx
Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach.
McFall T et al.
Cell Reports, 2021
Costello syndrome: Clinical phenotype, genotype, and management guidelines.
Gripp KW et al.
American Journal of Medical Genetics. Part A, 2019
Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.
Said R et al.
Oncotarget, 2014
Kinetic mechanisms of mutation-dependent Harvey Ras activation and their relevance for the development of Costello syndrome.
Wey M et al.
Biochemistry, 2013
Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development.
Siegel DH et al.
The British Journal of Dermatology, 2012
Ras and Rap signaling in synaptic plasticity and mental disorders.
Stornetta RL et al.
The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry, 2011
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y et al.
Human Mutation, 2008
Ampullary carcinoma-A genetic perspective.
Jayaramayya K et al.
Mutation Research. Reviews in Mutation Research, 0
Select a paper to view details